Kevin Conroy: Katherine is an incredible reminder of the 20-year impact Oncotype DX has made on breast cancer

Kevin Conroy, Chairman and CEO at Exact Sciences, shared on LinkedIn:

“Our patients are at the heart of everything we do at Exact Sciences. Meet Katherine, our first-ever Oncotype DX Breast Recurrence Score test patient. I was thrilled to connect with her recently.

Katherine was diagnosed with breast cancer in 2004 and was able to forgo chemotherapy after receiving her test results. She’s an incredible reminder of the 20-year impact Oncotype DX has made on breast cancer and aiding in personalized treatment decisions.”

Source: Kevin Conroy/LinkedIn